This is the seventh NMPA-approved indication of TYVYT® (sintilimab injection). The first six indications of TYVYT® (sintilimab injection) are inclu...
Under the terms of the agreement, Acorda will receive an up-front payment of $2.5 million, a near term milestone payment of up to $6 million, $3 million up...
Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. jointly announced that the IND application was approved in China for t...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA)...
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, resear...
ASC40 is an oral, selective small molecule inhibitor of FASN. Mechanisms of ASC40 for acne are (1) direct inhibition of facial sebum production, through in...
These new patents complement the company's strong international portfolio of 20 families and more than 78 patents covering the concept, design, production ...
Adcentrx Therapeutics ("Adcentrx"), a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other li...
-The revenue from innovative drugs accounted for more than 65% of total revenue -Simcere's total revenue and the revenue from in...
BBM-H901 is indicated for prophylactic treatment of bleeding in adults with hemophilia B. It is the first adeno-associated virus (AAV) gene therapy for Hem...
With the collaboration, Zylox Medical, the Company's peripheral vascular business unit, plans to launch the "Zylox-Hicicare Guidewire Family" products to a...
Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towa...
Agena Bioscience and nRichDX have advanced their existing technical collaboration to a commercial partnership that co-promotes their products to researcher...
The news of China’s move to dramatically increase its biotech sector, including genetic engineering, without first ensuring ample security measures i...
© 2024 Biopharma Boardroom. All Rights Reserved.
